表紙
市場調查報告書

間質性膀胱炎治療藥的全球市場:2019年∼2023年

Global Interstitial Cystitis Drugs Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 785654
出版日期 內容資訊 英文 117 Pages
訂單完成後即時交付
價格
間質性膀胱炎治療藥的全球市場:2019年∼2023年 Global Interstitial Cystitis Drugs Market 2019-2023
出版日期: 2019年01月29日內容資訊: 英文 117 Pages
簡介

間質性膀胱炎病因未完全闡明,認可的藥物,未認證的藥物幾乎為小分子,無法完全治療這個疾病。各公司致力於能完全治療的藥物開發。全球間質性膀胱炎治療藥市場預測至2023年將以3%的年複合成長率 (CAGR) 擴大。

本報告提供全球間質性膀胱炎治療藥市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的供應商簡介等相關資訊彙整。

第1章 摘要整理

第2章 報告的範圍

第3章 市場情況

  • 市場生態系統
  • 市場特長
  • 市場區隔分析

第4章 市場規模

  • 市場定義
  • 市場規模:2018年
  • 市場規模與預測:2018∼2023年

第5章 波特的五力分析

第6章 各類型市場區隔

  • 市場區隔
  • 比較
  • 口服治療
  • 膀胱內治療
  • 市場機會

第7章 客戶趨勢

第8章 各地區趨勢

  • 各地區市場區隔
  • 比較
  • 北美
  • 歐洲
  • 亞洲
  • 其他
  • 主要國家
  • 市場機會

第9章 促進要素與課題

第10章 市場趨勢

第11章 供應商環境

第12章 供應商分析

  • 網羅的供應商
  • 供應商分類
  • 市場定位
  • Bayer AG
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Mylan N.V.
  • Pfizer Inc.

第13章 附錄

目錄
Product Code: IRTNTR30726

About this market

The advent of gene therapy to drive market growth. Interstitial cystitis is characterized by urinary urgency and frequency, pelvic pain, and nocturia. However, only a few approved treatments are available, and curable treatments for the disease have not been identified yet. Although the etiology of the disease is not fully understood, usually, a bladder affected by interstitial cystitis is characterized by a thin and denuded urothelium. Most of the approved drugs and off-label drugs are small molecules, and they cannot completely cure the disease. Moreover, owing to the side effects and high costs of the available drugs, companies can establish new innovative treatment options such as regenerative therapy and gene therapy that have fewer side effects. Companies are also trying to develop a drug that can completely cure the disease. Technavio's analysts have predicted that the interstitial cystitis drugs market will register a CAGR of almost 3% by 2023.

Market Overview

Increasing awareness of interstitial cystitis

Although interstitial cystitis is one of the significantly prevalent bladder diseases, many people are unaware of it as most of the symptoms are very similar to other bladder-related diseases. Hence, educating people and making them aware of interstitial cystitis are very important. Many government and non-government organizations are conducting various programs to increase the awareness of the disease.

Lack of approved drugs

The treatment of interstitial cystitis consists of oral therapy and intravesical therapy as the first- and second-line treatment options, respectively. However, no single treatment works for all people with the disease. The treatment is based on the symptoms of each patient. Most of the patients try different treatments (or combinations of treatments) to get rid of the symptoms. Currently, the global interstitial cystitis drugs market has only two approved drugs, ELMIRON and RIMSO-50 (dimethyl sulfoxide). These drugs are proven their efficacy over the symptomatic treatments. However, these drugs are expensive. Therefore, many patients use off-label drugs largely to relieve the symptoms of the disease.

For the detailed list of factors that will drive and challenge the growth of the interstitial cystitis drugs market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Mylan N.V and Pfizer the competitive environment is quite intense. Factors such as the increasing awareness of interstitial cystitis and the advent of gene therapy, will provide considerable growth opportunities to interstitial cystitis drugs manufactures. Bayer AG, Eli Lilly and Company, Johnson & Johnson Services, Mylan N.V, and Pfizer are some of the major companies covered in this report.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY TYPE

  • Market segmentation by type
  • Comparison by type
  • Oral therapy - Market size and forecast 2018-2023
  • Intravesical therapy - Market size and forecast 2018-2023
  • Market opportunity by type

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer AG
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • Mylan N.V.
  • Pfizer Inc.

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Type - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by type
  • Exhibit 20: Oral therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Oral therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Intravesical therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Intravesical therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by type
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 02: Funds for research on interstitial cystitis
  • Exhibit 03: Overlapping of the symptoms of interstitial cystitis
  • Exhibit 04: Impact of drivers and challenges
  • Exhibit 05: Strategic alliances in the global interstitial cystitis drugs market
  • Exhibit 06: Vendor landscape
  • Exhibit 07: Landscape disruption
  • Exhibit 08: Vendors covered
  • Exhibit 09: Vendor classification
  • Exhibit 10: Market positioning of vendors
  • Exhibit 11: Bayer AG - Vendor overview
  • Exhibit 12: Bayer AG - Product segments
  • Exhibit 13: Bayer AG - Organizational developments
  • Exhibit 14: Bayer AG - Geographic focus
  • Exhibit 15: Bayer AG - Segment focus
  • Exhibit 16: Bayer AG - Key offerings
  • Exhibit 17: Bayer AG - Key customers
  • Exhibit 18: Eli Lilly and Company - Vendor overview
  • Exhibit 19: Eli Lilly and Company - Business segments
  • Exhibit 20: Eli Lilly and Company - Organizational developments
  • Exhibit 21: Eli Lilly and Company - Geographic focus
  • Exhibit 22: Eli Lilly and Company - Segment focus
  • Exhibit 23: Eli Lilly and Company - Key offerings
  • Exhibit 24: Eli Lilly and Company - Key customers
  • Exhibit 25: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 26: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 27: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 28: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 29: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 30: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 31: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 32: Mylan N.V. - Vendor overview
  • Exhibit 33: Mylan N.V. - Business segments
  • Exhibit 34: Mylan N.V. - Organizational developments
  • Exhibit 35: Mylan N.V. - Geographic focus
  • Exhibit 36: Mylan N.V. - Key offerings
  • Exhibit 37: Mylan N.V. - Key customers
  • Exhibit 38: Pfizer Inc. - Vendor overview
  • Exhibit 39: Pfizer Inc. - Business segments
  • Exhibit 40: Pfizer Inc. - Organizational developments
  • Exhibit 41: Pfizer Inc. - Geographic focus
  • Exhibit 42: Pfizer Inc. - Segment focus
  • Exhibit 43: Pfizer Inc. - Key offerings
  • Exhibit 44: Pfizer Inc. - Key customers
  • Exhibit 45: Validation techniques employed for market sizing
  • Exhibit 46: List of abbreviations